Search

You searched for "ureter"

477 results found

Fournier’s gangrene

1 May 2015 | | URO - Infection
Introduction Fournier’s gangrene (FG) is a rare but fulminant form of infective necrotising fasciitis affecting the perineum and external genitalia, which can rapidly progress along fascial planes. It most commonly affects men, but can occur in women and children, with...

The burning issue of urinary tract infections

1 September 2018 | | URO - Infection, URO - Functional / Reconstructive Urology
Urinary tract infections (UTIs) occur when bacteria colonise and proliferate in the urinary tract. These are characterised by specific clinical symptoms (dysuria, suprapubic tenderness, urgency and urinary frequency) which commonly occur alongside the finding of bacteriuria. UTIs are common –...

Penile cancer: a practical approach

6 November 2020 | | URO - Urologic Oncology
Penile cancer is rare and accounts for less than 1% of all new cancer cases in males in the UK, with around 640 new cases diagnosed every year [1]. In England and Wales, the annual incidence is between 1.2 and...

Sexual dysfunction following prostate cancer treatment

4 March 2024 | | URO - Andrology, URO - Urologic Oncology
Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...

The role of embolisation in urology

3 September 2024 | | URO - Functional / Reconstructive Urology, URO - Urologic Oncology
Case 1 An 86–year–old male presented with visible haematuria and suprapubic pain. He had a history of diabetes, heart failure, benign prostatic hypertrophy, aortic valve replacement, deep vein thrombosis (DVT) and atrial fibrillation (AF) and was anticoagulated on a non-VKA...

Use of Clavien-Dindo classification in urology part 1 – pelvic surgery

1 March 2016 | | URO - Urologic Oncology
There is no widely accepted system to classify postoperative complications. It is necessary to compare the outcome and complications while validating a new surgical procedure or one of the surgical approaches of a particular condition. Several parameters have long been...

What’s in a name?

1 March 2016 |
Kate Granger is a doctor and the founder of the #hellomynameis campaign; she is also a cancer patient. In this article she explains why she started the campaign, and why patient-centred care starts with an introduction. Chris and me the...

Localised renal cancer

4 September 2025 | | URO - Urologic Oncology, URO - Uroradiology
Case 1 A 56-year-old lady is referred to the urology clinic after the GP conducted an ultrasound abdomen for deranged liver function tests and found a renal lesion. She is otherwise fit and well. Figure 1. What is the sensitivity...

In conversation with Matthew Bultitude

27 November 2025 | URO - Core Urology
Matthew Bultitude. Can you tell us a little bit about what led you into the field of urology and what have been the highlights so far? Thank you and that is a very interesting question given that my father was...

A practical guide to success in National Selection

1 January 2014 | | URO - Core Urology
Gidon Ellis and Jonathan Makanjuola were both selected at National Selection in 2012 for Urological Higher Surgical Training. Both were ranked first in their respective interview rounds that year. It is no mean feat. Having read their article – their...

Thermal ablative techniques for small renal masses

1 July 2017 | | URO - Urologic Oncology, URO - Technology
The incidence of renal cell carcinoma has increased over the past decade which can be partly attributed to the increased use of imaging modalities [1,2]. Nephron sparing procedures for the management of small renal tumours have gained popularity which include...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...